Tweet
Hi everyone, Is there anyone who has worked with the Polyphen-2 standalone application??
-
-
I have some problems working with this. Please If someone has worked with it, guide. -
E-mail me your questions.Originally posted by shum1 View Post
Best,
Ivan Adzhubey <[email protected]>Comment
-
Hi,
Polyphen2 is a great tool for SNP annotations, works great with dbSNP annotations too!
For one of our projects we were trying to identify the dbSNP database version used...is it dbSNP137?
If so, is there a way we could download the database you use for the annotations?
Thanks much!Comment
-
dbSNP rsIDs found in the PolyPhen-2 output are obtained from Swiss-Prot protein annotations. This is a smaller subset (about 60,000) of manually verified human dbSNP rsIDs for missense SNPs only. They are not tied to a particular dbSNP build.Originally posted by rpauly View Post
dbSNP rsIDs which are found in the MapSNPs output (Batch query pipleine) are taken from UCSC Genome Browser snp135 track. These correspond to dbSNP build 135.
I am not sure I understand which database you want to download?Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment